FDA Clears First Self-Balancing Personal Exoskeleton for Spinal Cord Injury

The FDA has cleared Eve, a self-balancing personal exoskeleton designed to help eligible wheelchair users with spinal cord injury walk and perform daily activities.

For people living with spinal cord injury, advances in rehabilitation technology can create new opportunities for mobility, independence, and participation in everyday life. A major development in this field has now emerged with the U.S. Food and Drug Administration clearing Eve, a self-balancing personal exoskeleton designed for eligible adults with spinal cord injury who use wheelchairs.

The FDA clearance represents an important milestone for wearable mobility technology. It also reflects the growing role of rehabilitation research in evaluating whether advanced assistive devices can move beyond controlled clinical environments and become practical tools for everyday use.

Kessler Foundation, a New Jersey-based rehabilitation research organization, was one of three U.S. research sites involved in the clinical study supporting the FDA clearance.

What Is Eve, the New Personal Exoskeleton?

Eve is a personal robotic exoskeleton developed to help eligible adults with spinal cord injury stand, walk, and perform selected activities of daily living without relying on their hands for support.

One of the technology's distinguishing features is its self-balancing capability. Rather than requiring the user to maintain balance through crutches or other assistive devices during every movement, the system is designed to provide balance assistance while the user operates the device through a remote control.

The technology is intended for use on level indoor surfaces and nearby outdoor areas. Users must also have a specially trained companion supervising use of the device.

This approach could be particularly meaningful for wheelchair users who want to incorporate upright mobility into selected parts of their daily routines while maintaining the ability to use a wheelchair as their primary form of mobility.

Clinical Research Supported FDA Clearance

The FDA clearance was supported by a three-site clinical trial involving people with spinal cord injury and their companions.

The participating research locations included Kessler Foundation, the James J. Peters Department of Veterans Affairs Medical Center in Bronx, New York, and the Walk in New York by Wandercraft walk center in New York City.

Researchers examined more than the technical performance of the exoskeleton. The clinical program also evaluated safety, training, usability, functional performance, and readiness for personal use.

Participants represented a range of spinal cord injury severities. Before completing the assessments, participants underwent structured training intended to help them learn how to operate the system safely.

The evaluations included functional and task-based activities designed to reflect situations users could encounter in everyday environments. Participants and companions were assessed on their ability to operate the technology and complete relevant activities.

The findings indicated that participants could learn to use Eve and that companions could also become familiar with the procedures needed to support safe use.

Why Self-Balancing Technology Matters

Balance is one of the major challenges associated with walking after spinal cord injury. Traditional exoskeleton systems may require users to rely on crutches, walkers, or other support equipment to maintain stability.

A self-balancing exoskeleton takes a different approach by incorporating balance control directly into the device.

This could potentially make certain activities more practical for eligible users. Hands-free capability may allow a person to interact with their surroundings, perform selected tasks, or use their upper limbs while standing or walking.

However, the device is not intended to replace wheelchairs for every aspect of mobility. Instead, it provides another mobility option for people who meet the eligibility requirements and have completed the necessary training.

Reported Benefits Extend Beyond Walking

Walking performance is an important measure when evaluating an exoskeleton, but the potential effects of upright mobility can extend beyond the ability to take steps.

According to information from Kessler Foundation, study participants reported improvements in several areas of daily life. These included aspects of health status, psychological well-being, endurance during everyday activities, lower-limb spasticity, and sitting balance.

Some participants also reported improvements in sleep quality as well as bladder and bowel function.

These findings are important because spinal cord injury can affect multiple aspects of physical and psychological health. Research into rehabilitation technologies therefore increasingly looks at how interventions influence overall quality of life rather than focusing exclusively on a single physical outcome.

It is important to recognize that individual results can vary. Reported improvements from a clinical study do not mean every person using an exoskeleton will experience the same benefits.

Kessler Foundation's Role in Rehabilitation Innovation

Kessler Foundation has played a significant role in rehabilitation research for decades. Founded in 1985, the nonprofit organization conducts research focused on improving outcomes for people with disabilities.

Its research programs address conditions including spinal cord injury, traumatic brain injury, stroke, multiple sclerosis, autism, and other neurological and developmental disabilities.

The organization's involvement in the Eve clinical study illustrates the importance of collaboration between researchers, technology developers, clinicians, participants, and caregivers.

Gail Forrest, PhD, director of the Tim and Caroline Reynolds Center for Spinal Stimulation at Kessler Foundation, emphasized that the research considered how users and companions could safely incorporate the technology into real-world activities.

Rodger DeRose, president and chief executive officer of Kessler Foundation, also described the FDA clearance as an example of how scientific research can contribute to practical solutions designed to increase independence, mobility, and participation.

What the FDA Clearance Means for Spinal Cord Injury Mobility

The clearance of Eve does not mean that exoskeleton technology is suitable for every person with spinal cord injury. Eligibility, training requirements, physical capabilities, environmental conditions, and medical considerations all play a role in determining whether a person can safely use a personal exoskeleton.

Instead, the FDA decision represents another step in the development of personalized mobility technology.

For the broader spinal cord injury community, the development is significant because it moves advanced exoskeleton technology closer to personal use outside traditional rehabilitation facilities.

Wandercraft plans to launch Eve commercially in the United States on September 17, 2026.

As these technologies become more available, continued research will be important to understand long-term use, accessibility, affordability, safety, user satisfaction, and the effects of incorporating exoskeleton-assisted walking into everyday life.

The Future of Exoskeleton Technology

The FDA clearance of Eve highlights how rehabilitation engineering and clinical research are increasingly coming together to address complex mobility challenges.

For eligible wheelchair users with spinal cord injury, a self-balancing personal exoskeleton could provide an additional way to experience upright mobility and participate in selected activities.

The significance of the technology extends beyond walking itself. Greater access to personalized mobility solutions could contribute to broader conversations about independence, accessibility, rehabilitation, and quality of life.

As research continues, the next generation of exoskeletons may become more personalized, easier to operate, and increasingly integrated into everyday environments.

For now, the FDA clearance of Eve marks a notable development in the evolution of spinal cord injury exoskeleton technology and demonstrates the potential of research-driven innovation to translate laboratory and clinical findings into real-world mobility options.

Source: Kessler Foundation, August 11, 2026.

Disclaimer: This article is for informational and educational purposes only. It is not medical advice and should not be used as a substitute for evaluation or guidance from a qualified healthcare professional. FDA clearance does not mean that Eve is appropriate for every person with spinal cord injury. Eligibility, safety, training, and suitability should be determined with qualified healthcare and rehabilitation professionals. Reported clinical outcomes may vary between individuals.